Moderna, Inc. (MRNA) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Moderna’s revenue went from $108M in fiscal 2016 to $1.9B in fiscal 2025, growth of about 37.8% a year.
Net income in fiscal 2025 was -$2.8B, a net margin of -145.2%; the best year in this period was 2021 with $12.2B.
Over the twelve months to September 30, 2026, revenue was $2.5B and net income -$2.8B.
Free cash flow was -$2.1B in fiscal 2025 and positive in 4 of the 10 years shown.
The diluted share count rose 540% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $1.9B | $3.2B | $6.8B | $19.3B | $18.5B | $803M | $60M | $135M | $206M | $108M |
| Gross profit | $707M | $1.1B | $1.8B | $2.2B | $13.8B | $15.9B | $795M | $60M | $135M | — | — |
| Operating income | -$2.9B | -$3.1B | -$3.9B | -$4.2B | $9.4B | $13.3B | -$763M | -$546M | -$413M | -$269M | -$224M |
| Net income | -$2.8B | -$2.8B | -$3.6B | -$4.7B | $8.4B | $12.2B | -$747M | -$514M | -$385M | -$256M | -$216M |
| EPS (diluted) | $-7.10 | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 | $-1.96 | $-1.55 | $-4.95 | $-4.18 | $-3.79 |
| R&D | $2.7B | $3.1B | $4.5B | $4.8B | $3.3B | $2.0B | $1.4B | $496M | $454M | $410M | $275M |
| Revenue growth | — | −39.9% | −52.8% | −64.5% | +4.3% | +2200.2% | +1238.3% | −55.6% | −34.4% | +89.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8B | -$1.9B | -$3.0B | -$3.1B | $5.0B | $13.6B | $2.0B | -$459M | -$331M | -$331M | $67M |
| Capital spending | -$185M | -$192M | -$1.1B | -$707M | -$400M | -$284M | -$68M | -$32M | -$106M | -$58M | -$33M |
| Free cash flow | -$2.0B | -$2.1B | -$4.1B | -$3.8B | $4.6B | $13.3B | $2.0B | -$491M | -$437M | -$390M | $34M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | $2M | $0 | $1.2B | $3.3B | $857M | $0 | $0 | — | — | — |
| Stock-based pay | $464M | $483M | $429M | $305M | $226M | $142M | $93M | $81M | $73M | $40M | $39M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $5.8B | $7.0B | $8.6B | $9.9B | $10.7B | $4.6B | $1.1B | $1.5B | $756M | $50M |
| Debt | — | $1.3B | $685M | $668M | $127M | $152M | $103M | $97M | $71M | — | — |
| Equity | — | $8.7B | $10.9B | $13.9B | $19.1B | $14.1B | $2.6B | $1.2B | $1.5B | -$551M | -$335M |
| Total assets | — | $12.3B | $14.1B | $18.4B | $25.9B | $24.7B | $7.3B | $1.6B | $2.0B | $1.1B | — |
| Shares (diluted) | 430M | 389M | 384M | 382M | 416M | 431M | 381M | 331M | 81M | 64M | 61M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 28.0% | 55.4% | 54.8% | 31.5% | 71.9% | 85.8% | 99.0% | 100.0% | 100.0% | — | — |
| Operating margin | -116.0% | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% | -95.0% | -910.0% | -306.0% | -130.9% | -206.4% |
| Net margin | -110.5% | -145.2% | -110.0% | -68.8% | 43.4% | 66.1% | -93.0% | -856.7% | -284.8% | -124.3% | -199.5% |
| FCF margin | -78.0% | -106.2% | -125.3% | -55.9% | 23.8% | 72.2% | 244.0% | -818.3% | -323.3% | -189.4% | 31.0% |
| ROIC | — | -24.5% | -33.6% | -23.1% | 42.7% | 85.4% | -22.6% | -42.8% | -20.4% | — | — |
| ROE | — | -32.6% | -32.7% | -34.0% | 43.7% | 86.3% | -29.2% | -43.7% | -25.1% | 46.4% | 64.6% |
Frequently asked questions
What is Moderna’s annual revenue?
$1.9B in fiscal 2025 and $2.5B over the twelve months to September 30, 2026.
How much profit does Moderna make?
Net income was -$2.8B in fiscal 2025 (net margin -145.2%).
Is Moderna’s revenue growing?
No: revenue fell 39.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.